June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Retinal Protection by Lactoferrin in the Murine Laser Model of Choroidal Neovascularization
Author Affiliations & Notes
  • Luke Dolezal
    University of Minnesota Medical School, Minneapolis, MN
  • Kevin Mar
    Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
  • Abrar Rageh
    Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
  • Michael Jordan
    University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND
  • Deborah Ferrington
    Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
  • Sandra Montezuma
    Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
  • Footnotes
    Commercial Relationships Luke Dolezal, None; Kevin Mar, None; Abrar Rageh, None; Michael Jordan, None; Deborah Ferrington, None; Sandra Montezuma, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3858. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Luke Dolezal, Kevin Mar, Abrar Rageh, Michael Jordan, Deborah Ferrington, Sandra Montezuma; Retinal Protection by Lactoferrin in the Murine Laser Model of Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3858. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The purpose of this study is to determine if endogenous and exogenous administered Lactoferrin (LF) can protect the retina from choroidal neovascularization (CNV) in the murine laser model of CNV. Endogenous murine LF was evaluated by comparing the response of Wild Type (WT) vs Lactoferrin knock out (LFKO) mice in the CNV laser model. The potential protective effect of exogenous LF was evaluated following intraperitoneal (IP) administration of bovine lactoferrin (bLF) in LFKO mice.

Methods: Four 532-nm argon laser spots were placed between the retinal vessels of each WT and LFKO mouse. At Day 7, CNV was measured both clinically and microscopically. Fluorescein Angiography (FA) was performed to grade the lesions based on the degree of hyperfluorescence/leakage from images taken using a Micron III (Phoenix Research Lab Inc) color digital camera. The CNV lesions were imaged using an Olympus FV1000 confocal microscope and analysis of the images was performed manually using Image J software. The first experiment compared a group of WT to LFKO mice with no treatment. The second experiment compared a group of LFKO mice treated with intraperitoneal (IP) injections of bLF to a control group of LFKO mice treated with PBS.

Results: Experiment #1: WT mice demonstrated a 31% smaller lesion volume (p=0.015) and 14% smaller height (p= 0.009) than LFKO mice (n=5/ group). Experiment #2: LFKO mice treated with bLF demonstrated a 26% smaller lesion volume (p=0.053) and 13% smaller lesion height (p=0.051) compared with the LFKO mice treated with PBS (n=8 bLF, n=9 PBS). FA demonstrated clinically significant leakage in 13% of the lesions in the LFKO group treated with PBS and 2% of the lesions in the LFKO treated with bLF.

Conclusions: Our results demonstrate the endogenous and exogenous LF anti-angiogenic activity in reducing the volume of the lesions in the CNV laser- induced animal model. Further study is needed to assess the LF clinical utility in the treatment of eye diseases in which neovascularization is involved.

Keywords: 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×